1Steinbild S, Arends J, Medinger M, et al. Metronomic antiangiogenie therapy with capeeitahine and celecoxib in advanced tumor patients--results of a phase Ⅱ study [ J ]. Onkologie, 2007,30 (12) : 629-635.
3Lee JJ, Kim TM, Yu SJ, et al. Single-agent capecitabine in patiants with metastatic colorectal cancer refractory to 5-fluorouracil/ leucovofin chemotherapy[ J]. Jap J Clin Oncol,2004,34 (7) :400- 404.
4Yen-Revollo, JL, Goldberg RM, McLeod HL Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? [J]. Clin Cancer Res, 2008,14( 1 ) : 8-13.
6Loven D, Belfry E, Yerushalmi R, et al. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients[ J]. Acta Oncol, 2008,47 ( 1 ) : 104-109.
二级参考文献51
1Loven D, Beery E, Yerushalmi R, et al. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduced VEGF and PDGF-BB levels in rectal carcinoma patients[ J]. Acta Oncol, 2008, 47( 1 ) :104 - 109.
2Garcia AA, Hirte H, Flemin Q, et al. Phase Ⅱ clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase Ⅱ consortia[J]. J Clin Oncol, 2008, 26(1):76 -82.
3Brodowicz T, Krzakowski M,Zwitter M,et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial[J]. Lung Cancer, 2006, 52(2) :155 - 163.
4Bottini A, Generali D, Brizzi MP, et al, Randomized phase Ⅱ trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients[J]. J Clin Oncol, 2006, 24(22) :3623 -3628.
5Franchi F, Grassi P, Ferro D, et al. Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer[J]. Eur J Cancer Care(Engl), 2007, 16(3):258-262
6Leong SP, Witte MH. Patterns of metastasis in human solid cancers[ J]. Cancer Treat Res, 2007,135:209 - 221.
7Folkman J. Angiogenesis[ J]. Annu Rev Med, 2006,57 : 1 - 18.
8Folkman J. Tumor angiogenesis: therapeutic implication [ J ]. N Engl J Med, 1971, 255:1182-1186.
9Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer[ J]. Cancer Res, 2000,60 : 1878 - 1886.
10Kerbel RS, Klement G, Pritchard KL, et al. Continuous low- dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic[ J]. Ann Oncol, 2002, 13(1):12-15.
